Monnet P D, Kane F, Konan-Waidhet D, Akpona S, Kora J, Diafouka F, Sess D, Sangare A, Yapo A E
Laboratoire de biochimie faculté de pharmacic, Abidian, Côte d'Ivoire.
Bull Soc Pathol Exot. 1996;89(4):278-81.
The main clinical use of measurements of Apo Al and Apo B is to determine a patient's risk status for the development of ischemic heart disease. Apo B is generally accepted as a contributory cause of coronary artery disease, while Apo Al apparently has a protective effect. The present study reports the plasma change of Apo Al and B in sickle cell anaemic subjects. Immunochemical findings revealed that Apo Al and B levels were found to be lower in sickle cell patients as compared with normal subjects (HbAA). The atherogenicity index given by Apo B/Apo Al remained in the normal range during periods of steady state (0.64 +/- 0.28), while subjects in painful crisis had high index values (0.95 +/- 0.35). Therefore, we concluded that epidemiological studies on a large sample of patients are needed to confirm this relationship between painful crisis and risk of developing coronary artery disease.
载脂蛋白A1(Apo Al)和载脂蛋白B(Apo B)测定的主要临床用途是确定患者发生缺血性心脏病的风险状况。Apo B通常被认为是冠状动脉疾病的一个促成因素,而Apo Al显然具有保护作用。本研究报告了镰状细胞贫血患者血浆中Apo Al和B的变化。免疫化学研究结果显示,与正常受试者(HbAA)相比,镰状细胞病患者的Apo Al和B水平较低。在稳定期,Apo B/Apo Al得出的致动脉粥样化指数保持在正常范围内(0.64±0.28),而处于疼痛危象期的受试者该指数值较高(0.95±0.35)。因此,我们得出结论,需要对大量患者进行流行病学研究,以证实疼痛危象与发生冠状动脉疾病风险之间的这种关系。